Immunic, Inc. Conference Participation in October
Immunic, Inc. (Nasdaq: IMUX), a biotechnology firm dedicated to developing innovative therapies for chronic inflammatory and autoimmune diseases, has made headlines with its participation in several important scientific and investor conferences throughout October.
Key Conferences to Attend
The company will be attending a series of significant events, showcasing its research and development efforts.
UEGW 2025 – United European Gastroenterology Week
From October 4-7, Immunic's R&D team will be present at the United European Gastroenterology Week in Berlin, Germany. At this highly regarded event, the company plans to present findings related to IMU-856, an oral small molecule modulator targeting SIRT6, through various formats including an oral presentation, a publication, and an electronic poster. You can find more details in the "Events and Presentations" section on the Immunic website.
Presentation Highlights:
- Title: IMU-856, an Orally Available Epigenetic Modulator of Barrier Regeneration, Showed Positive Effects on Gut Hormone Levels in Celiac Disease Patients in a Phase 1 Clinical Study
- Presenting Author: Amelie Schreieck, Ph.D., Senior Manager of Biomarker Development at Immunic
- Session Title: Molecular Medicine: Understanding Mechanisms to Enable Therapy
- Location: Room A3
International Society of Neuroimmunology Congress
Following the UEGW, from October 5-8, Immunic will also participate in the 17th International Congress of the International Society of Neuroimmunology (ISNI) taking place in Chiba, Japan. At this conference, Dr. Evelyn Peelen will discuss findings related to vidofludimus calcium (IMU-838), an exciting new candidate in Immunic's portfolio.
Poster Presentation:
- Title: Nurr1 Activator Vidofludimus Calcium Exhibits Signs of Neuroprotection in Preclinical Models
- Session Title: Poster Session 2
- Location: Room 101B-105
Healthcare Opportunities Conference
On October 9, Immunic's CEO, Dr. Daniel Vitt, will take part in a panel discussion at Roth's 4th Annual Healthcare Opportunities Conference in New York. This event is an excellent platform for promoting discussion surrounding the future of biotechnology and investment opportunities.
Panel Discussion Details:
- Panel Topic: Next Wave of Innovation in Underserved Indications
- Panel Time: 2:00 - 2:55 pm ET
H.C. Wainwright Fireside Chat
Wrapping up the month, on October 23, Dr. Vitt and Jason Tardio, Immunic's President and COO, will engage in a virtual fireside chat. This event is scheduled for 11:00 am ET and offers an opportunity for the public to gain insights into the company's direction.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is at the forefront of biotechnology with a robust pipeline focused on the treatment of chronic inflammatory and autoimmune disorders. Currently, the firm is advancing vidofludimus calcium (IMU-838) through phase 3 clinical trials for relapsing multiple sclerosis, with anticipated data to emerge shortly. In addition, Immunic is pioneering IMU-856, which aims to rebuild intestinal barriers affected by various gastrointestinal diseases. The commitment to impactful research highlights the company's mission to innovate therapeutic approaches that can significantly improve patient outcomes.
Frequently Asked Questions
What is the focus of Immunic, Inc.?
Immunic, Inc. focuses on developing small molecule therapies aimed at treating chronic inflammatory and autoimmune diseases.
Where will Immunic participate in October conferences?
Immunic will participate in the UEGW in Berlin, the ISNI Congress in Chiba, and Roth's Healthcare Opportunities Conference in New York.
What are some key presentations from Immunic?
Key presentations include studies on IMU-856 and vidofludimus calcium, showcasing innovative findings in neuroprotection and gastroenterology.
How can one access Immunic's presentations?
Presentations and ePosters will be accessible on the "Events and Presentations" section of Immunic's official website.
What is vidofludimus calcium?
Vidofludimus calcium (IMU-838) is a nuclear receptor-related 1 (Nurr1) activator undergoing phase 3 trials for treating relapsing multiple sclerosis.
